Remove 2019 Remove Clinical Trials Remove Events Remove History
article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials. The Court’s order permits petitioners to return to the Court of Appeals “in the event” that DEA engages in “significant delays” in the future.

DEA 103
article thumbnail

Cannabis laws in Japan: Is weed legal?

The Cannigma

However, the country has a history of cannabis art dating back millenia , and scholars believe that the plant was used for centuries as a textile and for use in traditional Shinto ceremonies. But in modern times? That could potentially change in the near future, however. Amphetamines are the most popular drug of choice in Japan.).

Law 137
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NORML 2019 Legislative Report

Cannabis Law Report

This report contains a detailed summary of 2019’s federal and state legislative victories.” 2019 has been an unprecedented year for the passage of state-level marijuana law reforms. “Never before in American history has marijuana policy advanced in Congress as far or as fast in one year as 2019.

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history.

article thumbnail

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Cannabis Law Report

Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year 1. January 15, 2019.

article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. In March 2019, J&J’s hard work paid off when the FDA approved Spravato for treatment-resistant depression. Hundreds of other U.S. cities are reportedly considering similar measures at the moment.

article thumbnail

The John Hopkins Center for Psychedelic and Consciousness Research Publishes Inaugural Edition Of Newsletter

Cannabis Law Report

Upcoming Events. November 21, 2019. Dr. Griffiths and Dr. Johnson will be speaking at Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks conference in Washington DC. December 3, 2019. December 4, 2019. December 6, 2019. December 8-11, 2019.

Therapy 59